The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Importantly, the combination of giredestrant and everolimus was well tolerated
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Subscribe To Our Newsletter & Stay Updated
